Recombinant VP1, an akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Chen, Tai An ^a   Wang, Jui Ling ^a   Hung, Shao Wen ^a   Chu, Chiao Li ^a   Cheng, Yung Chih ^a   Liang, Shu Mei ^a  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 9; KU ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BAX; PROTEIN KINASE B INHIBITOR; RECOMBINANT VP1 PROTEIN; UNCLASSIFIED DRUG; CAPSID PROTEIN; PROTEIN KINASE B; RECOMBINANT PROTEIN; VP1 PROTEIN, FOOT AND MOUTH DISEASE VIRUS; VP1 PROTEIN, FOOT-AND-MOUTH DISEASE VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISSOCIATION; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME INACTIVATION; IC 50; IMMUNOCOMPETENCE; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; MITOCHONDRIAL PERMEABILITY; MOUSE; NONHUMAN; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER TUMOR; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING;

FOOT-AND-MOUTH DISEASE VIRUS; MIRIDAE; MURINAE; MUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CAPSID PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHEMOKINE CCL2; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER NEOPLASMS; MICE; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS;

EID: 79961053391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023317     Document Type: Article

References (54)

1. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
2. Shirabe K, Takenaka K, Taketomi A, Kawahara N, Yamamoto K, et al. (1996) Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 77: 1050-1055.
3. Takayasu K, Wakao F, Moriyama N, Muramatsu Y, Yamazaki S, et al. (1992) Postresection recurrence of hepatocellular carcinoma treated by arterial embolization: analysis of prognostic factors. Hepatology 16: 906-911.
4. Greten TF, Korangy F, Manns MP, Malek NP, (2009) Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 100: 19-23.
5. Pang RW, Poon RT, (2007) From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72 (Suppl 1): 30-44.
6. Llovet JM, Bruix J, (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (Suppl 1): S20-S37.
7. Voiculescu M, Winkler RE, Moscovici M, Neuman MG, (2008) Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic. J Gastrointestin Liver Dis 17: 315-322.
8. Mahfouz M, Hashimoto W, Das Gupta TK, Chakrabarty AM, (2007) Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy. Plasmid 57: 4-17.
9. Kooistra K, Zhang YH, Noteborn MH, (2007) Viral elements sense tumorigenic processes: approaching selective cancer therapy. Mini Rev Med Chem 7: 1155-1165.
10. Branton PE, Roopchand DE, (2001) The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene 20: 7855-7865.
11. Shtrichman R, Sharf R, Barr H, Dobner T, Kleinberger T, (1999) Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A. Proc Natl Acad Sci USA 96: 10080-10085.
12. Belsham GJ, (1993) Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure. Prog Biophys Mol Biol 60: 241-260.
13. Peng JM, Liang SM, Liang CM, (2004) VP1 of foot-and-mouth disease virus induces apoptosis via the Akt signaling pathway. J Biol Chem 279: 52168-52174.
14. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, et al. (2003) Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 5: 320-329.
15. Gama V, Gomez JA, Mayo LD, Jackson MW, Danielpour D, et al. (2009) Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization. Cell Death Differ 16: 758-769.
16. Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, et al. (2007) Bax activation and mitochondrial insertion during apoptosis. Apoptosis 12: 887-896.
17. Dagouassat M, Suffee N, Hlawaty H, Haddad O, Charni F, et al. (2010) Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. Int J Cancer 126: 1095-1108.
18. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, et al. (2009) A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16: 295-308.
19. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, et al. (2007) CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101: 676-685.
20. Vande BI, Asosingh K, Vanderkerken K, Straetmans N, Van CB, et al. (2003) Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1,-2 and-3. Br J Cancer 88: 855-862.
21. Mestdagt M, Polette M, Buttice G, Noel A, Ueda A, et al. (2006) Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast cancer cells. Int J Cancer 118: 35-42.
22. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, et al. (2006) Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66: 1311-1318.
23. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, et al. (1999) Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 81: 855-859.
24. Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, et al. (2004) Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 25: 14-17.
25. Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, et al. (2011) Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 44: 230-237.
26. Craig MJ, Loberg RD, (2006) CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev 25: 611-619.
27. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, et al. (2009) CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284: 34342-34354.
28. Tarzami ST, Calderon TM, Deguzman A, Lopez L, Kitsis RN, et al. (2005) MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G(alphai)-independent pathway. Biochem Biophys Res Commun 335: 1008-1016.
29. Yang NS, Wang JH, Lin KF, Wang CY, Kim SA, et al. (2005) Comparative studies of the capsid precursor polypeptide P1 and the capsid protein VP1 cDNA vectors for DNA vaccination against foot-and-mouth disease virus. J Gene Med 7: 708-717.
30. Wang JH, Liang CM, Peng JM, Shieh JJ, Jong MH, et al. (2003) Induction of immunity in swine by purified recombinant VP1 of foot-and-mouth disease virus. Vaccine 21: 3721-3729.
31. Shieh JJ, Liang CM, Chen CY, Lee F, Jong MH, et al. (2001) Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization. Vaccine 19: 4002-4010.
32. Desai N, Trieu V, Yao Z, Louie L, Ci S, et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12: 1317-1324.
33. Hayashi T, Nakao K, Nagayama Y, Saitoh O, Ichikawa T, et al. (2005) Vaccination with dendritic cells pulsed with apoptotic cells elicits effective antitumor immunity in murine hepatoma models. Int J Oncol 26: 1313-1319.
34. Zhang K, Loong SL, Connor S, Yu SW, Tan SY, et al. (2005) Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice. Clin Cancer Res 11: 7532-7537.
35. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, et al. (2007) Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46: 1119-1130.
36. Ara T, Declerck YA, (2010) Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46: 1223-1231.
37. Thompson WL, Van Eldik LJ, (2009) Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes. Brain Res 1287: 47-57.
38. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, et al. (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63: 7451-7461.
39. Amaravadi R, Thompson CB, (2005) The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618-2624.
40. Osaki M, Oshimura M, Ito H, (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676.
41. Fabregat I, Roncero C, Fernandez M, (2007) Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 27: 155-162.
42. Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H, (2001) Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34: 55-61.
43. Beerheide W, Tan YJ, Teng E, Ting AE, Jedpiyawongse A, et al. (2000) Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas. Biochem Biophys Res Commun 273: 54-61.
44. Rashmi R, Kumar S, Karunagaran D, (2004) Ectopic expression of Bcl-XL or Ku70 protects human colon cancer cells (SW480) against curcumin-induced apoptosis while their down-regulation potentiates it. Carcinogenesis 25: 1867-1877.
45. Ayene IS, Ford LP, Koch CJ, (2005) Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation. Mol Cancer Ther 4: 529-536.
46. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM, (2010) Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61: 317-328.
47. Tung-Ping PR, Fan ST, Wong J, (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10-24.
48. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y, (1990) Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 66: 2174-2179.
49. Zhang J, Patel L, Pienta KJ, (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21: 41-48.
50. Hayden MS, Ghosh S, (2004) Signaling to NF-kappaB. Genes Dev 18: 2195-2224.
51. Lucito R, Schneider RJ, (1992) Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C. J Virol 66: 983-991.
52. Tietze MK, Wuestefeld T, Paul Y, Zender L, Trautwein C, et al. (2000) IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther 7: 1315-1323.
53. Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, et al. (2000) Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 89: 2274-2281.
54. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr, (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417.